Skip to main content
XCUR
NASDAQ Life Sciences

Exicure Signs Parkinson's Device Deal; Plans 20%-100% NeuroQ Stake Via Share Issuance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.92
Mkt Cap
$5.966M
52W Low
$0.777
52W High
$9.48
52W Position info
18% above low
Off High info
90% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

XCUR sits 18% above its 52-week low of $0.777 on light trading volume (0.1× avg).

Summary

Exicure signed a November 19 agreement with NeuroQ Biologics and Laonz to move into Parkinson's disease smart-glasses technology, intending to buy 20% to 100% of NeuroQ largely with Exicure shares and fund up to $500,000 of development. Final terms, share ratio and approvals are still open.


Key Events · M&A and Partnerships · XCUR

  • Parkinson's Device Expansion Agreement

    On November 19, 2026 Exicure entered a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. covering X-CUE augmented-reality smart glasses for Parkinson's freezing of gait.

  • Stock-Funded 20%-100% NeuroQ Stake

    Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily by issuing Exicure common shares in exchange for NeuroQ shares held by Laonz; the final percentage and share exchange ratio are undetermined.

  • Up to $500,000 Development Funding

    Following the share acquisition, Exicure intends to provide up to US$500,000 for X-CUE clinical evaluation, regulatory work, manufacturing preparation and commercialization, subject to approvals and funding availability.

  • Terms and Approvals Still Open

    Final acquisition percentage, exchange ratio and other terms require subsequent written agreements plus corporate, regulatory and Nasdaq approvals; X-CUE's planned clinical evaluation is expected to run about six months.


Analysis · XCUR · Life Sciences

Exicure is pivoting part of its business into Parkinson's disease medical devices through a new agreement with NeuroQ Biologics and Laonz. The company intends to acquire 20% to 100% of NeuroQ, paid mostly in Exicure stock rather than cash, and to put up to $500,000 into developing the X-CUE smart-glasses technology. That structure matters for a company this small: the share-based purchase means dilution whose size is still unknown, and the $500,000 funding commitment is a real cash call against a balance sheet that already carried a going concern warning. No acquisition percentage, exchange ratio, or definitive terms are set yet, so the deal is an intent, not a completed transaction. It also lands days before the December 2, 2026 shareholder vote on a $10 million private placement authorization and ahead of the December 2, 2026 Nasdaq equity-compliance deadline.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XCUR was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.78 to $9.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XCUR - Latest Insights

XCUR
Nov 16, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.95995 info
Change: -$0.11005 (-10%) info
Market Cap: $6.023M info
XCUR
Nov 10, 2026, 3:50 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.95995 info
Change: -$0.12105 (-11%) info
Market Cap: $6.023M info
XCUR
Nov 10, 2026, 3:50 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.95995 info
Change: -$0.12105 (-11%) info
Market Cap: $6.023M info
XCUR
Nov 02, 2026, 5:25 PM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.95995 info
Change: -$0.10005 (-9%) info
Market Cap: $6.023M info
XCUR
Sep 16, 2026, 10:27 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $0.95995 info
Change: -$0.34505 (-26%) info
Market Cap: $6.023M info